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Christelle Ferra,1 Jaime Sanz,2 Rafael de la Camara,3 Guillermo Sanz,2 Arancha Bermudez,4
David Valcarcel,5 Montserrat Rovira,6 David Serrano,7 Dolores Caballero,8
lldefonso Espigado,9 Mireia Morgades,1 Inmaculada Heras,10 Carlos Solano,11
Rafael Duarte,12 Cristina Barrenetxea,13 Ana Garcıa-Noblejas,3 Jose L. Dıez-Martin,7
Arturo Iriondo,4 Enric Carreras,6 Jordi Sierra,5 Miguel-Angel Sanz,2 Josep-Maria Ribera,1 on
behalf of GETH (Grupo Espan˜ol de Trasplante Hematopoyetico) and PETHEMA (Programa
Espan˜ol de Tratamiento en Hematologıa), Spanish Society of HematologyAdults with high-risk acute lymphoblastic leukemia (HR-ALL) have a poor outcome with standard chemo-
therapy and usually undergo unrelated stem cell transplantation (SCT) if a matched sibling donor is not avail-
able. We analyzed the outcome of adult patients with unrelated SCT for HR-ALL and studied the possible
effect of the hematopoietic stem cell source of the transplant. A total of 149 adult patients (median age,
29 years, range, 15-59 years) with HR-ALL underwent unrelated SCT in 13 Spanish institutions between
2000 and 2007. Patients in first complete remission (CR1) at transplantation had at least one adverse prog-
nostic factor (advanced age, adverse cytogenetics, hyperleukocytosis, or slow response to induction ther-
apy). ALL was in CR1 in 81 patients (54%), in second CR (CR2) in 37 patients (25%), in third CR (CR3) in
11 patients (7%), and with overt disease in 20 patients (13%). The hematopoietic source was unrelated
cord blood (UCB) in 62 patients and an unrelated donor (UD) in 87 patients. The patients undergoing
UCB-SCTand UD-SCTwere comparable in terms of the main clinical and biological features of ALL, except
for a higher frequency of patients with more overt disease in the UCB-SCT group. There was no statistically
significant difference in overall survival (OS) or disease-free survival (DFS) at 5 years between the 2 groups.
Treatment-related mortality (TRM) was significantly lower in the UCB-SCT group (P5.021). The probability
of relapse at 1 year was 17% (95% confidence interval [CI], 7%-27%) for the UD-SCT group and 27% (95%CI,
14%-40%) for the UCB-SCT group (P5 .088), respectively. Only disease status at transplantation (CR1, 41%
[95% CI, 18%-64%] vs CR2, 51% [95% CI, 17%-85%] vs advanced disease, 66% [95% CI, 46%-86%]; P5 .001)
and the absence of chronic graft-versus-host disease (74% [95% CI, 46%-100%] vs 33% [95% CI, 17%-49%];
P 5 .034) were significant factors for relapse. All unrelated transplantation modalities were associated with
high treatment-related mortality for adult HR-ALL patients without a sibling donor. UCB-SCTand UD-SCT
were found to be equivalent options. Disease status at transplantation and chronic GVHD were the main
factors influencing relapse in both transplantation modalities.
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Table 1. PatientCharacteristics According toHematopoietic
Progenitor Source
UCB-SCT
(n 5 62)
UD-SCT
(n 5 87) P
Age, years, mean (SD) 29 (9) 31 (11) .180
Sex, M/F, n 39/23 51/36 .598
Diagnosis, n (%) .138
B-lineage ALL 43 (69) 68 (78)
T-lineage ALL 14 (23) 14 (16)
Unspecified ALL 5 (8) 2 (2)
No data 0 3 (3)
Cytogenetics, n (%) (n 5 41) (n 5 66) .053
Normal 3 (7) 6 (9)
t(9;22) 26 (63) 39 (59)
t(4;11) 5 (12) 4 (6)
Complex 0 3 (5)
Other abnormality 7 (17) 13 (20)
No growth 0 1 (2)
Extramedullary involvement
at diagnosis, n (%)
3 (5) 6 (7) .194
Disease status at transplantation, n
(%)
.047
CR1 35 (56) 46 (53)
CR2 10 (19) 27 (31)
CR3 3 (5) 8 (9)
Refractory 6 (10) 3 (3)
Relapsed 8 (13) 3 (3)
ALL indicates acute lymphoblastic leukemia; UCB-SCT, unrelated cord
blood stem cell transplantation; UD-SCT, unrelated donor stem cell
transplant; SD, standard deviation; CR1, first complete remission;
CR2, second complete remission; CR3, third complete remission.
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Adults with acute lymphoblastic leukemia (ALL)
with high-risk features at diagnosis, recurrent disease,
or slow response have a poor outcome with standard
chemotherapy. Autologous stem cell transplantation
(SCT) has not proved to provide any advantage for
ALL patients in complete remission (CR), because
of a high frequency of relapse [1,2]. Despite a high
frequency of treatment-related mortality (TRM), allo-
geneic SCT remains the best therapeutic option in
high-risk ALL [3-8]. High-risk adult ALL patients
have a very poor outcome, with an expected disease-
free survival (DFS) of only 35%-45% in many trials
[9,10]. Consequently, in most transplantation
centers, these patients are considered for alternative-
donor SCT when a matched sibling donor is not avail-
able [11-14]. The alternative hematopoietic source can
be a nonidentical relative, an unrelated donor (UD), or
unrelated cord blood (UCB) units [15-22].
Long-term results of UD-SCT in adult patients
are scarce, and the best unrelated progenitor source
remains unclear. To date, no comparative study on
the outcomes of adult ALL patients in Western coun-
tries who underwent UD-SCT based on the stem cell
source has been published; the only related study is
a recent report comparing unrelated bone marrow
(BM) and UCB-SCT in Eastern adult patients with
acute leukemia [23].
We retrospectively analyzed the outcome of
adult patients undergoing unrelated SCT for poor-
prognosis ALL in 13 transplantation centers in Spain
between 2000 and 2007, focusing on the hematopoi-
etic stem cell (HSC) source.METHODS
Patients
A total of 149 adult patients (median age, 29 years;
range, 15-59 years) with poor- prognosis ALL under-
went an unrelated SCT in 13 Spanish institutions
between 2000 and 2007. ALL was of precursor B cell
lineage in 111 patients (74%), of T cell lineage in 28
patients (19%), and of undetermined lineage in 10
patients (7%). ALLwas in first CR (CR1) in 81 patients
(54%), in second CR (CR2) in 37 patients (25%), in
third CR (CR3) in 11 patients (7%), and with overt dis-
ease in 20 patients (13%). Patients were treated with
PETHEMA ALL-93 trial [10] or PETHEMA ALL-
AR03 trial [24] protocols. After 2003, 39 patients with
Philadelphia chromosome–positive ALL were treated
with the CSTIBES02 trial protocol and received imati-
nib in combination with chemotherapy and SCT [25],
with 25 undergoing UD-SCT and 14 undergoing
UCB-SCT. The median time from diagnosis to SCT
was 0.85 years (range, 0.08-16.48 years) for UD-SCTand 0.72 years (range, 0.06-11.10 years) for UCB-
SCT.The hematopoietic progenitor sourcewas a single
unmanipulated UCB unit in 62 patients (41%),
mobilized peripheral blood in 41 patients (28%), and
unmodified BM in 46 patients (31%) (Table 1).
High-risk ALL was defined as in PETHEMA
ALL-93 trial [10]. The criteria for indicating an unre-
lated SCT in CR1 was the presence of at least one of
the following adverse prognostic factors: aged .30
years, white blood cell count (WBC) .30  109/L,
adverse cytogenetics (t [9; 22], t [4;11] or other
11q23 rearrangements, and t[1;19]), or slow response
to induction therapy (defined as .10% blasts in BM
on day 15 of induction therapy).SCT Procedure
Before 2004, UD selection was based on HLA se-
rotyping performed for class I antigens (HLA-A and
-B antigens) and high-resolution genotyping for class
II antigens (HLA-DR), and required 5 or 6 of 6 iden-
tities. After 2004, the requirements included 7 or 8 of 8
allelic identities (HLA-A, -B, -C, and -DR). The re-
quirements for UCB-SCT were 4-6 of 6 HLA-A/-B
antigenic and -DR allelic identities.
Conditioning therapy consisted of total body irra-
diation (TBI) and cyclophosphamide (Cy) in 68
patients (46%), busulfan (Bu) and Cy in 9 patients
(6%), thiotepa-Bu-Cy or fludarabine in 60 patients
Table 2. Pretransplantation Characteristics According to
Hematopoietic Progenitor Source
UCB-SCT
(n 5 62)
UD-SCT
(n 5 87) P
HLA incompatibility <.001
No 3 54
Yes 59 33
ABO barrier .781
No 21 34
Minor 19 23
Major 18 25
Recipient/donor sex .187
M/M 4 32
M/F 7 14
F/M 3 19
F/F 4 13
Conditioning therapy <.001
TBI + CY 2 66
BU + CY 0 9
Thiotepa + BU + CY/FLU 58 2
Other myeloablative therapy 2 10
GVHD prophylaxis <.001
CyA + methotrexate 1 72
CyA + prednisone 53 0
CyA + mycophenolate 6 8
Other 2 7
ATG <.001
Yes 61 16
No 1 71
TBI <.001
Yes 3 67
No 58 20
UCB-SCT indicates unrelated cord blood stem cell transplantation;
UD-SCT, unrelated donor stem cell transplant; M, male; F, female; TBI,
total body irradiation; Cy, cyclophosphamide; Bu, busulfan; Flu, fludarab-
line; GVHD, graft-versus-host disease; CsA, cyclosporine A; ATG,
antithymocyte globulin.
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another regimen in 12 patients (8%) (Table 2).
Definitions of Outcomes
Leukocyte and platelet engraftment were defined
as an absolute neutrophil count (ANC) .0.5  109/L
in the first of 3 consecutive days and a platelet count
.20  109/L in the first of 7 consecutive days without
transfusion support, respectively. Graft failure was de-
fined as the absence of neutrophil recovery at day130
after UD-SCT or at day 160 after UCB-SCT. Pa-
tients with graft failure were censored for the assess-
ment of graft-versus-host disease (GVHD). Acute
graft-versus-host disease (aGVHD) was diagnosed
and graded using standard criteria [26] and was
assessed only in patients who achieved engraftment
or survived for .30 days. Chronic GVHD (cGVHD)
was assessed in patients who survived .100 days and
was graded as limited or extensive according to classi-
cal criteria [27,28].
TRMwas defined as any death related to the trans-
plantation procedure and not to relapse. CR was con-
sidered as normal reconstitution of BM cellularity with
\5% leukemic blasts and a neutrophil count .1.5 
109/L together with a platelet count .100  109 /L,
along with the absence of any clinical evidence of leu-
kemia. Relapse was defined as morphological evidence
of leukemia in BM or other sites in a patient previously
in CR. Overall survival (OS) was calculated from the
time of transplantation to death from any cause, and
disease-free survival (DFS) was defined as the time
from transplantation to either first relapse or to death
in CR. Only patients with a first allogeneic SCT were
considered for the study; any patients who underwent
a second transplantation because of nonengraftment of
the first one were censored at the time of the second
transplantation.
Statistical Analysis
The major endpoint of this study was to analyze
OS and DFS in adult patients with high-risk ALL
who underwent unrelated SCT with cord blood
progenitors, BM, or mobilized peripheral blood pro-
genitors. An analysis restricted to patients who under-
went transplantation in CR1 was performed. Patient
and disease characteristics were compared for categor-
ical variables using the c2 or Fisher’s exact test and for
continuous variables using bivariate tests (Student t
test, Mann-Whitney U test, or analysis of variance as
appropriate). Survival probabilities were estimated by
the Kaplan-Meier method [29] and were compared
with data from the log-rank test. Only the variables
that were significantly different (P\ .05) or with bor-
derline significance (P\ .15) in the univariate analysis
were included in the Cox proportional hazard regres-
sion model. Cumulative incidence curves were usedin a competing-risk setting to calculate the probability
of relapse and TRM. For relapse, death without re-
lapse was the competing event; for TRM, relapse was
the competing event. TheGray test was used for group
comparisons of cumulative incidence [30]. All statisti-
cal tests except cumulative incidence with competing
risks (performed with R version 2.7.0; R Foundation
for Statistical Computing) were performed using
SPSS version 15.0 (SPSS, Chicago, IL).RESULTS
Patients and Transplantation Procedures
Patients and transplantationcharacteristics are sum-
marized in Tables 1 and 2. No differences were found
in terms of BM versus peripheral blood progenitors;
thus, both sources of UD-SCT were considered to-
gether for comparisonwithUCB-SCT. Patients receiv-
ing UCB-SCT and UD-SCT were comparable for the
main clinical and biological variables Table 1. The
UCB-SCT group included more patients with adverse
cytogenetics (t[9;22] and t[4;11]) and active disease (re-
fractory and relapsed patients) (Table 1). As expected,
in the latter group of patients, HLA incompatibility
Table 3. Transplant Characteristics According to Hemato-
poietic Progenitor Source
UCB-SCT
(n 5 62)
UD-SCT
(n 5 87) P
Graft cellularity <.001
CD34+ cells, 106/kg,
median (range)
0.26 (0.06-2.84) 5 (1.47-14)
Engraftment, n (%)
Neutrophil graft failure
(<0.5  109/L, d +30)
9/58 (16) 2/83 (2) .006
Neutrophil graft failure
(<0.5  109/L, d +60)
4/58 (7) 1/83 (1) .092
Platelet graft failure
(d +120)
6/48 (13) 0/68 (0) .004
Median days to ANC
>0.5  109/L
20 (12-52) 16 (10-34) .039
Median days to platelet
count >20  109/L
46 (24-141) 14.50 (3-90) <.001
Acute GVHD, n (%) (n 5 58) (n 5 83)
Grade >I 30 (52) 62 (75) .005
Grade III-IV 10 (17) 23 (28) .149
Chronic GVHD, n (%) (n 5 31) (n 5 57)
Limited 6 (19) 9 (16) .671
Extensive 12 (39) 29 (51) .274
Hemorrhagic cystitis, n (%) 9 (15) 7 (8) .209
Microangiopathy, n (%) 2 (3) 5 (6) .700
Bacterial infection, % 31 36 .347
Fungal infection, % 17 21 .651
CMV infection or disease, % 26 27 .171
Sinusoidal hepatic obstructive
syndrome, n (%)
4/50 (8) 12 / 86 (14) .299
Cause of death, n (%) .001
Relapse/disease progression 13 (21) 11 (13)
GVHD and infection 4 (6) 23 (26)
Infection 11 (18) 11 (13)
Interstitial pneumonia 0 6 (7)
Graft failure 3 (5) 0
Sinusoidal hepatic
obstructive syndrome
0 3 (3)
Miscellaneous 3 (5) 3 (3)
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus.
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Figure 1. TRM and relapse rate for patients undergoing UD-SCT and
UCB-SCTestimated by competing-risk analysis.
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(thiotepa-Bu-Cy or fludarabine and antithymocyte
globulin [ATG]) differed from that used in the UD-
SCT group (Table 2). Before 2004, 38 patients
(25.5%) underwent SCT from a 6/6-matched UD,
and 4 patients (3%) did so from a 5/6-matched UD. Af-
ter 2004, 38 patients (25.5%) underwent SCT from an
8/8-matched UD, and 10 patients (7%) did so from
a 7/8-matched UD. In the UCB-SCT group, 1 patient
had received 3/6-matched UCB unit, 39 patients
(26%) received 4/6-matched UCB units, 16 patients
(11%) received 5/6-matched UCB units, and only 3 pa-
tients (2%) received 6/6-matched UCB units. A total of
81 patients (35 in the UCB-SCT group and 46 in the
UD-SCT group) underwent SCT while in CR1.
Engraftment and Posttransplantation
Complications
The time to hematologic recovery was longer and
the frequency of graft failure was higher in the UCB-
SCT group compared with the UD-SCT group
(Table 3). No difference in the incidence of bacterial,fungal, or viral infections was seen between the 2
groups.Ninety-twopatients (63%) developed aGVHD
grade I or higher, and 15 (17%) and 41 (47%) of 88
evaluable patients developed limited cGVHD and
extensive cGVHD, respectively. No significant dif-
ferences in the incidence of severe aGVHD (grades
III-IV) or of limitedor extensive cGVHDwere seenbe-
tween the UD-SCT and UCB-SCT groups (Table 3).
The incidences of hemorrhagic cystitis, microangio-
pathy, and hepatic obstructive sinusoidal syndrome
were similar in the 2 groups.TRM
EstimatedTRM at 1 year was significantly lower in
theUCB-SCT group (31% [19%-43%] vs 48% [36%-
58%]; P5 .023) (Figure 1). The major causes of death
differed in the 2 groups, with relapse or disease pro-
gression the main causes in the UCB-SCT group
and GVHD and infection the main causes in the
UD-SCT group (Table 3).
In the univariate analysis, factors predictive of
a higher TRM were stem cell source (with a higher
TRM in the UD-SCT group), WBC count at diagno-
sis .30  109/L, presence of severe aGVHD, and
presence of extensive cGVHD. There was a trend
toward a higher TRM for patients receiving TBI in
the conditioning regimen (P 5 .058) and for patients
aged.30 years (P5 .069). In the multivariate analysis,
only severe aGVHD was significantly associated with
a higher risk of TRM (OR, 4.237; 95% CI, 2.232-
8.00; P\ .001), however (Table 4).
For those patients undergoing transplantation in
CR1, a highWBC count at diagnosis, severe aGVHD,
and extensive cGVHD were associated with higher
Table 4. Univariate and Multivariate Analyses of Variables Affecting Transplantation Outcome in All Patients
5-Year, % (95% CI) P OR (95% CI) P
OS
Lymphocyte lineage, B/ T 25% (13%-37%)/23% (7%-39%) .093 NS
WBC >30  109/L, yes/no 10% (0-22%)/24% (8%-40%) .028 NS
aGVHD, yes/no 22% (12%-32%)/41% (24%-58%) .080 NS
Severe aGVHD (grade III-IV), yes/no 9% (0-10%)/32% (19%-45%) <.001 3.02 (1.71, 5.38) <.001
DFS
WBC >30  109/L, yes/no 11% (0-24%)/23% (8%-38%) .066 NS
Severe aGVHD (grade III-IV), yes/no 9% (0-19%)/27% (16%-38%) <.001 3.88 (2.04, 7.35) <.001
TRM
Age >30 years, yes/no 69% (49%-89%)/43% (30%-56%) .069 NS
Stem cell source, UCB/UD 39% (24%-54%)/63% (49%-77%) .023 NS
WBC >30  109/L, yes/no 84% (67%-100%)/57% (39%-75%) .021 NS
aGVHD, yes/no 58% (46%-70%)/35% (16%-54%) .024 NS
Severe a GVHD (grade III-IV), yes/no 87% (75%-99%)/39% (26%-52%) <.001 4.24 (2.23, 8.00) <.001
ATG, yes/no 41% (25%-54%)/60% (46%-74%) .106 NS
Extensive cGVHD, present/absent 51% (32%-70%)/17% (6%-28%) .030 NS
TBI, yes/no 65% (50%-80%)/53% (33%-73%) .058 NS
Relapse
Disease status, CR1/CR2/>CR2 41% (18%-64%)/51% (17%-85%)/66% (46%-86%) .001 1/3.23 (1.06-9.80)/4.36 (1.82-10.53) .003
Severe aGVHD (grade III-IV), yes/no 12% (0-35%)/54% (38%-70%) .055 NS
cGVHD, present/absent 33% (17%-49%)/74% (46%-100%) .034 3.01 (1.32-6.83) .009
Extensive cGVHD, present/absent 31% (12%-50%)/58% (37%-79%) .129 NS
ATG, yes/no 62% (41%-83%)/34% (16%-52%) .137 NS
TBI, yes/no 38% (17%-59%)/59% (39%-79%) .139 NS
NS indicates not significant.
Biol Blood Marrow Transplant 16:957-966, 2010 961Unrelated Transplantations for Poor-Prognosis Adult ALLrisk of TRM in the univariate analysis. Only
a leukocyte count at diagnosis .30  109/L was un-
equivocally associated with a high TRM in the
multivariate analysis (Table 5).Relapse Rate
The overall relapse rate was 15% (95% CI, 10%-
20%) at 1 year, 22% (95% CI, 15%-29%) at 2 years,
and 29% (95% CI, 20%-38%) at 5 years. There was
no difference in the relapse probability in the UD-
SCT and UCB-SCT groups, with a median time to
relapse of 38.87 months (range, 16.43-61.30 months)
for the UCB-SCT group and not achieved for theTable 5. Univariate and Multivariate Analyses of Variables Affect
plantation in CR1 (n 5 81)
5 Year, % (95% CI)
OS
WBC >30 109/L, yes/no 7% (0%-22%)/32% (7%-57%
Severe aGVHD (grade III-IV), yes/no 11% (0%-26%)/38% (18%-58
aGVHD, yes/no 29% (14%-44%)/59% (27%-
Extensive cGVHD, present/absent 29% (5%-53%)/61% (34%-8
DFS
WBC >30 109/L, yes/no 9% (0%-24)/30% (9%-51%)
Severe aGVHD (grade III-IV), yes/no 11% (0%-26%)/29% (12%-46
Extensive cGVHD, present/absent 26% (5%-47%)/42% (15%-6
TRM
WBC >30  109/L, yes/no 91% (76%-100%)/50% (26%
Lymphocyte lineage, B/T 54% (38%-70%)/73% (44%-
aGVHD, yes/no 60% (45%-75%)/26% (4%-4
Severe aGVHD (III-IV), yes/no 41% (23%-59%)/89% (74%-
cGVHD, yes/no 47% (26%-68%)/16% (0%-33
Extensive cGVHD, present/absent 60% (35%-85%)/12% (0%-25
Relapse No variable showed a significan
NS indicates not significant; CR1, first complete remission; OR, odds ratio; OS,
tality; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-hUD-SCT group. The factors influencing relapse rate
in univariate analysis were TBI-containing condition-
ing, absence of ATG as GVHD prophylaxis, develop-
ment of grade III-IV aGVHD, development of
cGVHD, and disease status in CR1 (Table 4). In mul-
tivariate analyses, the only factors associated with
lower relapse rate were disease status in CR1 and the
development of cGVHD (Table 4 and figures 2A and
B).OS and DFS
The median follow-up after SCT was 20 months
(range, 0.3-101.4 months) for the whole group, 23ing Transplantation Outcome in Patients Undergoing Trans-
P OR (95% CI) P
) .017 NS
%) <.001 NS
91%) .096 NS
8%) .049 NS
.065 3.7 (1.03, 13.33) .045
%) <.001 NS
9%) .123 NS
-74%) .007 4.05 (1.13-14.49) .032
100%) .092 NS
8%) .084 NS
100%) <.001 NS
%) .148 NS
%) .008 NS
t influence on transplantation outcome.
overall survival; DFS, disease-free survival; TRM, treatment-related mor-
ost disease.
Figure 3. DFS and OS for patients undergoing UD-SCT (A) and UCB-
SCT (B).
Figure 2. Relapse rate depending on the ALL status at transplantation
(A) and on the presence of cGVHD (B).
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20 months (range, 0.3-96.0 months) for UCB-SCT
(P 5 not significant [NS]). The median OS was 10
months (95% CI, 4-17 months) for the whole group,
9 months (95% CI, 2-17 months) for UD-SCT, and
15 months (95% CI, 7-22 months) for UCB-SCT
(Figure 1A). For patients in CR1, the median OS was
12 months (95% CI, 0-29 months) for the whole
group, 27 months (95% CI, 2-51) for UD-SCT, and
10 months (95 CI%, 0-23 months) for UCB-SCT.
The estimated OS for the whole group was 47%
(95% CI, 38%-56%) at 1 year, 40% (95% CI, 31%-
49%) at 2 years, and 26% (95% CI, 17%-35%) at
5 years. The estimated 5-year OS was 22% (95% CI,
11%-33%) for UD-SCT and 33% (95% CI, 18%-
48%) for UCB-SCT. On univariate analysis, factors
associated with lower OS probability were WBC
count .30  109/L at diagnosis (P 5 .028) and grade
III-IV aGVHD (P\ .001); however, only the presence
of severe aGVHD was associated with a poorer out-
come on multivariate analysis (Table 4).The median DFS was 7 months (95% CI, 3-11
months) for the whole group, 5 months (95% CI,
2-9 months) for UD-SCT, and 9 months (95% CI,
1-17 months) for UCB-SCT (Figure 3B). The esti-
mated DFS for the whole group was 43% (95% CI,
34%-52%) at 1 year, 33% (95% CI, 24%-42%) at 2
years, and 21% (95% CI, 13%-29%) at 5 years. The
estimated DFS at 5 years was 21% (95% CI, 11%-
31%) for UD-SCT and 22% (95% CI, 8%-36%) for
UCB-SCT. For patients in CR1, the median DFS
was 12 months (95% CI, 2-22 months) for the whole
group, 12 months (95% CI, 2-22 months) for UD-
SCT, and 10 months (95% CI, 0-26 months) for
UCB-SCT (P 5 NS). In univariate analysis, the sole
factor associated with lower DFS probability was the
presence of grade III-IV aGVHD (P\ .001), which
was confirmed in multivariate analysis (OR, 3.876;
95% CI, 2.041-7.353; P\ . 001) (Table 4).
No significant differences in OS or DFS at 5 years
were seen between the UCB-SCT and UD-SCT
groups (Figure 1A and B). Neither was any significant
Biol Blood Marrow Transplant 16:957-966, 2010 963Unrelated Transplantations for Poor-Prognosis Adult ALLdifference in OS and DFS detected between patients
undergoing an 8/8 allele–matched UD-SCT and those
undergoing a 4-6/6-matched UCB-SCT. In addition,
no significant differences were observed in DFS or
OS between the periods 2000-2003 and 2004-2007,
or on comparison with centers reporting more versus
fewer than 15 UD-SCTs (data not shown). For those
patients undergoing transplantation in CR1, even
though severe aGVHD and extensive cGVHD were
associated with a worse DFS and OS, only a high leu-
kocyte count was found to influence DFS in multivar-
iate analysis (Table 5).DISCUSSION
Our findings demonstrate that UCB-SCT and
UCB-SCT are associated with high TRM and a poor
long-term DFS and OS in poor-prognosis ALL adult
patients without a sibling donor. Severe aGVHD was
found to be the most important factor for OS, DFS,
and TRM. In contrast, only disease status at the time
of transplantation and the presence of cGVHD
affected the relapse rate in this group of patients.
Several previous studies have described outcomes
of UCB-SCT and compared them with those of
UD-SCT [19-21,31]; however, these studies included
both acute myelogenous and lymphoid leukemias,
and some included some proportion of pediatric
patients. Moreover, OS, DFS, and TRM were
usually estimated for short periods (1-3 years),
leading to underestimation of late TRM.
Three major studies compared the outcomes of
ALL after unrelated SCT, focusing on the HSC
source. One of these studies was performed in pediat-
ric patients, in whom CB is now a well-established
stem cell source [32]. The second was a large study
of Japanese adults with acute leukemia involving a dis-
ease-specific comparison [23]. In that study, mobilized
peripheral bloodwas not used as a stem cell source, and
BMwas always 8/8 genotypically matched. In the ALL
group, no differences in TRM, OS, or DFS were seen
in patients receiving BM or UCB as the stem cell
source; there was only a trend for a higher cumulative
incidence of relapse and a significant lower incidence
of cGVHD and aGVHD in the UCB recipients. The
University of Minnesota group reported their long-
term experience with TBI-based myeloablative SCT
in adult and pediatric patients with ALL [33], noting
poor outcomes with autologous SCT and similar out-
comes for related donor, UD, and UCB SCT [33].
To the best of our knowledge, our study is the larg-
est published report in Western adult patients with
high-risk ALL receiving unrelated hematopoietic pro-
genitors for SCT. Our findings indicate that the stem
cell source was not relevant to patient outcome.
Although we found a lower TRM in patients receivinga UCB-SCT, this did not translate to a better OS or
DFS. As in previous reports, the patients undergoing
UCB-SCT had worse prognostic factors than those
undergoing UD-SCT (ie, more advanced disease
status at transplantation and a higher prevalence of
t[9;22] rearrangement). Although some previous data
have pointed toward a worse prognosis in patients
receiving mobilized peripheral blood compared with
those receiving BM in the unrelated setting for ALL
[34], we detected no such difference in our study.
One relevant finding in the present study is the low
expected long-term survival (when considered at 5
years). But this study included a very-high-risk ALL
population, in whom TRM and relapse rate turned
out to be higher than those for patients who underwent
allogeneic SCT for acute myelogenous leukemia [23].
Moreover, the long follow-up allowed observation of
late events (ie, relapse or death related to cGVHD)
that decreased the life expectancy in these patients.
Moreover, even if some authors might consider
.100  109 lymphoblasts/L, but .30  109 lympho-
blasts/L as an adverse prognostic factor in patients
with ALL of T cell ineage, none of the patients in
this study presented with this adverse prognostic
factor.
In contrast to other reports [35], we found no sig-
nificant impact of HLAmismatch onOS orDFS in the
UD-SCT group (data not shown). This might because
of the limited number of patients undergoing UD-
SCT in this study, however. Moreover, we found no
difference in survival between patients undergoing an
8/8-matched UD-SCT and those undergoing a 4-6/
6-matched UCB-SCT.
For patients undergoing SCT in CR1, a high
WBC count at diagnosis was the strongest predictor
of survival in multivariate analysis. For such patients,
the presence of aGVHD and cGVHD influenced sur-
vival and TRM in univariate analysis. However, unlike
in the whole series, this was not confirmed in multivar-
iate analysis, probably because of the small number of
patients analyzed.
The main limitations of the present study are re-
lated to its retrospective nature. Only a study random-
izing UCB-SCT and UD-SCT could unequivocally
answer the question of the best hematopoietic progen-
itor source for unrelated SCT in adult ALL patients;
however, such a study would be very difficult or almost
impossible to perform in patients with a suitable UD
and suitable unrelated UCB units. We restricted our
study to the period 2000-2007. Since 2004, high-
resolution HLA class I and II determination has been
common practice in UD searches in Spain; thus, we
compared the outcomes between the periods 2000-
2003 and 2004-2007, and found them to be similar.
The second limitation is the study’s multicenter
setting, with possible heterogeneity in the high-risk
criteria used to evaluate patients’ suitability for
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inclusion criteria for this study found that most of
the patients fulfilled more than one of these criteria.
The third study limitation is related to the impossibil-
ity of studying the impact of cGVHDonTRM, relapse
rate, or survival with the newly defined National Insti-
tutes of Health standards [36], given the study’s multi-
center and retrospective nature. Applied in future
prospective studies, these standards will be more accu-
rate in evaluating cGVHD after each modality of
unrelated SCT. Finally, in cases with more than one
option (UD or UCB), we cannot know which criteria
were used in each institution to select one source or
the other. However, in many centers even today, a rea-
sonably matched UD (8-10/10) is preferred to UCB
(which is inevitably mismatched in most cases).
Despite the well-known delayed immune reconsti-
tution and greater infectious vulnerability after UCB-
SCT [18,37,38], the incidence of infectious episodes in
our study was similar in the UCB-SCT and UD-SCT
groups. The incidence of death attributed exclusively
to infection (not associated with the presence of
GVHD) also was similar in the 2 groups. The main
cause of death was disease relapse in the UCB-SCT
group and GVHD in the UD-SCT group.
The incidence of severe aGVHD found in our
study is higher than that reported by previous studies
of unrelated SCT [11,13,39,40], especially when
the source of stem cells was unrelated peripheral
blood or BM. The high incidence of HLA mismatch
in our series, the absence of ATG in the
conditioning therapy in most patients, and, finally,
the genetic heterogeneity in the Spanish population
(in contrast to the Scandinavian or Japanese
population) may be responsible for this difference in
GVHD rate. The antileukemic activity of GVHD
traditionally has been considered weaker in ALL
than in other hematologic diseases; however, many
authors [11,41-44] have shown the antileukemic
effect of cGVHD, especially the limited type, in
adult patients undergoing both related and unrelated
allogeneic SCT. In our study, the presence of
cGVHD and ALL status at transplantation were the
strongest factors influencing relapse, similar to what
has been reported in the related transplantation
setting [2,6,40,45,46]. Even if the presence of cGVHD
protected against relapse in our study, it had no
significant impact on OS or DFS, probably because
of the numerous factors that interfere with survival in
the unrelated transplantation setting. The graft-
versus-leukemia effect of cGVHD has been found to
be stronger in patients with translocations (including
Philadelphia chromosome–positive ALL) [44] or
with normal diploid cytogenetics than in patients
with deletions or numeric abnormalities [41]. We
could not prove such an effect in this group of patients
in our study, however (data not shown). As expected,the presence of severe aGVHD had a strong adverse
effect on patient outcome; however, it had a positive
impact on decreasing the relapse rate, as has been re-
ported previously [13,14]. This effect might become
more advantageous if we could reduce the nonrelapse
mortality associated with severe aGVHD.
Conditioning regimens that include TBI have
been associated with improved DFS in ALL patients
undergoing autologous or allogeneic SCT [47]. Our
exploration of the particular effect of TBI on the re-
lapse rate of the whole group revealed a trend toward
a higher relapse rate in the patients who did not receive
TBI. But these patients were mostly recipients of UCB
progenitors, who had a significantly lower rate of
cGVHD, which was one of the most important factors
in preventing relapse in multivariate analysis. The use
of ATG in all UCB-SCT recipients also could have
contributed to the higher relapse rate in this group.
When examining the impact of TBI in the UD-SCT
group, we found no influence on relapse rate. Disease
status at the time of transplantation and the presence of
cGVHD were the main factors influencing relapse in
adult patients with high-risk ALL after an unrelated
SCT. The lower incidence of GVHD seen in the
UCB-SCT group could explain the trend toward
a higher relapse rate in these patients.
Previously explored strategies to reduce TRM
in UCB-SCT have included reduced-intensity
conditioning, double or multiple grafts [15,37,48],
third-party infusions [21], and intrabone UCB admin-
istration [49,50]. In the present study, all patients in
the UCB-SCT group received a single UCB graft
with standard administration techniques. In the
UD-SCT setting, generalized high-resolution typing
methods [51] and more efficient transmission of data
by the donor registries should improve the clinical out-
come in patients with a high-risk ALLwithout a sibling
donor. Improvements are also needed in the manage-
ment and modulation of GVHD and prevention of
relapse in these patients.
In conclusion, based on our results, UCB or UD
hematopoietic progenitors should be indiscriminately
considered for unrelated transplantation in poor-risk
adult ALL patients without a sibling donor. Factors
influencing relapse are similar to those observed in
SCT from HLA-identical siblings. This study sup-
ports the unrestricted use of either HSC source in
adult patients with high-risk ALL without a histocom-
patible related donor.ACKNOWLEDGMENTS
The authors thank the physicians, nurses, and other
support staff who cared for the patients during the
transplantation procedures, as well as the clinical inves-
tigation teams at each participating institution who
Biol Blood Marrow Transplant 16:957-966, 2010 965Unrelated Transplantations for Poor-Prognosis Adult ALLprovided data collection and follow-up. The following
transplantation centers contributed to this study:
Hospital La Fe (Valencia), Hospital de la Princesa
(Madrid), Hospital Marques de Valdecilla (Santander),
Hospital Sant Pau (Barcelona), Hospital Clınic (Barce-
lona), Hospital Gregorio Maran˜on (Madrid), Hospital
Universitario de Salamanca, Hospital Universitari
Germans Trias i Pujol (Badalona), Hospital Virgen
del Rocıo (Sevilla), Hospital Morales Meseguer
(Murcia), Hospital Clınico Universitario (Valencia),
Hospital Duran i Reynals (L’Hospitalet de Llobregat),
and Hospital Vall d’Hebron (Barcelona).
Financial disclosure: This work was supported by
grants from the Jose Carreras Leukaemia Foundation
(PEF-08) and RETIC, Instituto Carlos III (RD 06/
0020/1056). The authors have not any conflict of in-
terest to declare.REFERENCES
1. BishopMR, Logan BR, Gandham S, et al. Long-term outcomes
of adults with acute lymphoblastic leukemia after autologous or
unrelated donor bone marrow transplantation: a comparative
analysis by the National Marrow Donor Program and Center
for International Blood and Marrow Transplant Research.
Bone Marrow Transplant. 2007;41:635-642.
2. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with
standard-risk acute lymphoblastic leukemia, the greatest benefit
is achieved from a matched sibling allogeneic transplantation in
first complete remission, and an autologous transplantation is
less effective than conventional onsolidation/maintenance che-
motherapy in all patients: final results of the International
ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;
111:1827-1833.
3. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al.
Allogeneic and autologous transplantation for haematological
diseases, solid tumours and immune disorders: definitions and
current practice in Europe. Bone Marrow Transplant. 2006;37:
439-449.
4. Thiebault A, Vernant JP, Degos L, et al. Adult acute lympho-
cytic leukemia study testing chemotherapy, and autologous
and allogeneic transplantation: follow-up reports of the French
protocol LALA 87. Hematol Oncol Clin North Am. 2000;14:
1353-1366.
5. ThomasX, Boiron JM,Huguet F, et al. Outcome of treatment of
adults with acute lymphoblastic leukemia: analysis of LAL-94
trial. J Clin Oncol. 2004;22:4075-4086.
6. Hallbo¨o¨k H, Ha¨gglund H, Stockelberg D, et al. Autologous and
allogeneic stem cell transplantation in adult ALL: the Swedish
Adult ALL Group experience. Bone Marrow Transplant. 2005;
35:1141-1148.
7. Marks DI, Aversa F, Lazarus HM. Alternative donor trans-
plants for adult acute lymphoblastic leukaemia: a comparison
of the three major options. Bone Marrow Transplant. 2006;38:
467-475.
8. Bachanova V, Weisdorf D. Unrelated donor allogeneic trans-
plantation for adult acute lymphoblastic leukaemia: a review.
Bone Marrow Transplant. 2008;41:455-464.
9. Hoelzer D, Go¨ckbuget N. New approaches in acute lympho-
blastic leukemia in adults. Where do we go? Semin Oncol.
2000;27:540-559.
10. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of
intensive chemotherapy, allogeneic or autologous stem cell
transplantation as post-remission treatment for adult patients
with high-risk acute lymphoblastic leukaemia: results ofthe PETHEMA ALL-93 trial. Haematologica. 2005;90:
1346-1356.
11. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow
transplantation for adult patients with poor-risk acute lympho-
blastic leukemia: strong graft-versus-leukemia effect and risk
factors determining outcome. Blood. 2001;97:1572-1577.
12. ChimCS, Lie AKW, AuWY, et al. Long-term results of alloge-
neic bone marrow transplantation for 108 adult patients with
acute lymphoblastic leukemia: favourable outcome with BMT
at first remission andHLA-matched related donor. BoneMarrow
Transplant. 2007;40:339-347.
13. Kiehl MG, Kraut L, Schwerdfeger R, et al. Outcome of alloge-
neic hematopoietic stem-cell transplantation in adult patients
with acute lymphoblastic leukemia: no difference in related com-
pared with unrelated transplant in first complete remission.
J Clin Oncol. 2004;22:2816-2825.
14. Fielding AK, Rowe JM,Richards SM, et al. Prospective outcome
data on 267 unselected adult patients with Philadelphia chromo-
some–positive acute lymphoblastic leukaemia confirms superi-
ority of allogeneic transplant over chemotherapy in the
pre-imatinib era: results from the international ALL trial
MRC UKALLXII/ECOG2993. Blood. 2009;113:4489-4496.
15. Schoemans H, Theunissen K, Maertens J, et al. Adult umbilical
cord blood transplantation: a comprehensive review. Bone Mar-
row Transplant. 2006;38:83-93.
16. Sanz GF, Saavedra S, Planelles D, et al. Standarized, unrelated
donor cord blood transplantation in adults with hematologic
malignancies. Blood. 2001;98:2332-2338.
17. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among
562 recipients of placental-blood transplants from unrelated do-
nors. N Engl J Med. 1998;339:1565-1577.
18. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-
cord blood or bone marrow from unrelated donors in adults
with acute leukaemia. N Eng J Med. 2004;351:2276-2285.
19. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after
transplantation of cord blood or bone marrow from unrelated
donors in adults with leukaemia. N Eng J Med. 2004;351:
2265-2275.
20. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative
analysis of unrelated bone marrow transplantation and cord
blood transplantation for adult patients with hematologic malig-
nancies. Blood. 2004;104:3813-3820.
21. Magro E, Regidor C, Cabrera R, et al. Early hematopoietic
recovery after single unit unrelated cord blood transplantation
in adults supported by co-infusion of mobilized stem cells
from a third-party donor. Haematologica. 2006;91:640-648.
22. Kamani N, Spellman S, Hurley CK, et al. State of the art review:
HLA matching and outcome of unrelated donor umbilical cord
blood transplants. Biol Blood Marrow Transplant. 2008;14:1-6.
23. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific
analyses of unrelated cord blood transplant compared with unre-
lated bone marrow transplant in adult patients with acute leuke-
mia. Blood. 2009;113:1631-1638.
24. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk
(HR) Philadelphia chromosome–negative (Ph-) adult acute
lymphoblastic leukemia (ALL) according to classical risk factors
and minimal residual disease (MRD): interim results of the
PETHEMA ALL-AR-03 Trial. 48th Annual Meeting of the
American Society of Hemaotology, Orlando, FL, December
9-12 [abstract 1872]. Blood. 2006;106:531a.
25. Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive
chemotherapy and imatinib before and after stem cell transplan-
tation in newly diagnosed Philadelphia chromosome–positive
acute lymphoblastic leukaemia: final results of the CSTIBES02
trial. Haematologica. 2010;95:87-95.
26. Przepiorka D, Weisdorf D, Martin P, et al. Consensus confer-
ence on acute GVHD grading. Bone Marrow Transplant. 1995;
15:825-828.
27. Sullivan KM, Agura E, Anesetti C, et al. Chronic graft-versus-
host disease and other late complications of bone marrow trans-
plantation. Semin Hematol. 1991;28:250-259.
966 Biol Blood Marrow Transplant 16:957-966, 2010C. Ferra et al.28. Atkinson K. Chronic graft-versus-host disease. Bone Marrow
Transplant. 1990;5:69-82.
29. Kaplan EL, Meier P. Non-parametric estimation from incom-
plete observations. J Am Stat Assoc. 1958;53:457-481.
30. Gray RJ. A class of k-sample tests for comparing the cumulative
incidence of a competiting risk. Ann Stat. 1988;16:1141-1154.
31. Barker JN, Davies SM, DeFor T, et al. Survival after transplan-
tation of unrelated donor umbilical cord blood is comparable to
that of human leukocyte antigen–matched unrelated donor bone
marrow: results of a matched-pair analysis. Blood. 2001;97:
2957-2961.
32. EapenM, Rubinstein P, ZhangMJ, et al. Outcome of transplan-
tation of unrelated donor umbilical cord blood and bonemarrow
in children with acute leukaemia: a comparison study. Lancet.
2007;369:1947-1954.
33. Tomblyn MB, Arora M, Baker S, et al. Myeloablative hemato-
poietic cell transplantation for acute lymphoblastic leukemia:
analysis of graft sources and long-term outcome. J Clin Oncol.
2009;27:3634-3641.
34. Garderet L, Labopin M, Gorin NC, et al. Patients with acute
lymphoblastic leukaemia allografted with a matched unrelated
donor may have a lower survival with a peripheral blood stem
cell graft compared to bone marrow. Bone Marrow Transplant.
2003;31:23-29.
35. Weisdorf D, Spellman S, Haagenson M, et al. Classification of
HLA-matching for retrospective analysis of unrelated donor
transplantation: revised definitions to predict survival. Biol Blood
Marrow Transplant. 2008;14:748-758.
36. Filipovich AH,Weisdorf D, Pavletic S, et al. National Institutes
of Health Consensus Development Project on Criteria for Clin-
ical Trials in Chronic Graft-Versus-Host Disease, I: Diagnosis
and Staging Working Group report. Biol Blood Marrow Trans-
plant. 2005;11:945-955.
37. Barker JN. Umbilical cord blood (UCB) transplantation: an
alternative to the use of unrelated volunteer donors? Hematol
Am Soc Hematol Educ Program. 2007;2007:55-61.
38. Parody R,Martino R, RoviraM, et al. Severe infections after un-
related donor allogeneic hematopoietic stem cell transplantation
in adults: comparison of cord blood transplantation with periph-
eral blood and bone marrow transplantation. Biol Blood Marrow
Transplant. 2006;12:734-748.
39. Dahlke J, Kro¨ger N, Zabelina T, et al. Comparable results in pa-
tients with acute lymphoblastic leukemia after related and unre-
lated stem cell transplantation. Bone Marrow Transplant. 2006;
37:155-163.
40. Doney K, Ha¨gglund H, Leisenring W, et al. Predictive factors
for outcome of allogeneic hematopoietic cell transplantationfor adult acute lymphoblastic leukemia. Biol BloodMarrow Trans-
plant. 2003;9:472-481.
41. Lee S, Cho BS, Kim SY, et al. Allogeneic stem cell transplanta-
tion in first complete remission enhances graft-versus leukemia
effect in adults with acute lymphoblastic leukemia: antileukemic
activity of chronic graft-versus host disease. Biol Blood Marrow
Transplant. 2007;13:1083-1094.
42. Zikos P, VanLintMT,Lamparelli T, et al. Allogeneic hemopoi-
etic stem cell transplantation for patients with high-risk acute
lymphoblastic leukemia: favorable impact of chronic graft-
versus-host disease on survival and relapse. Haematologica.
1998;83:896-903.
43. Nordlander A, Mattsson J, Ringden O, et al. Graft-versus-host
disease is associated with a lower relapse incidence after hemato-
poietic stem cell transplantation in patients with acute lympho-
blastic leukemia. Biol Blood Marrow Transplant. 2004;10. 195–20.
44. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse
and overall survival in Philadelphia chromosome–positive acute
lymphoblastic leukemia after transplantation. Biol Blood Marrow
Transplant. 2003;9:206-212.
45. Grigg AP, Szer J, Beresford J, et al. Factors affecting the out-
come of allogeneic bone marrow transplantation for adult
patients with refractory or relapsed acute leukaemia. Br J Hae-
matol. 1999;107:409-418.
46. Kumar P, Defor TE, Brunstein C, et al. Allogeneic hematopoi-
etic stem cell transplantation in adult acute lymphocytic leuke-
mia: impact of donor source in survival. Biol Blood Marrow
Transplant. 2008;14:1394-1400.
47. Granados E, De La Camara R, Madero L, et al. Hematopoietic
cell transplantation in acute lymphoblastic leukaemia: better
long-term event-free survival with conditioning regimens con-
taining total body irradiation.Hematologica. 2000;85:1060-1067.
48. Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after
umbilical cord blood transplantation: enhanced graft-versusleu-
kemia effect in recipients of 2 units. Blood. 2009;114:4293-4299.
49. Frassoni F, Gualandi F, Podesta`M, et al. Direct intrabone trans-
plant of unrelated cord-blood cells in acute leukaemia: a phase
I/II study. Lancet Oncol. 2008;9:831-839.
50. Brunstein CG, Barker JN, Weisdorf DJ, et al. Intra-BM injec-
tion to enhance engraftment after myeloablative umbilical
cord blood transplantation with two partially HLA-matched
units. Bone Marrow Transplant. 2009;43:935-940.
51. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of
HLA class I and II high-resolution matching on outcomes of
unrelated donor bone marrow transplantation: HLA-C is asso-
ciated with a strong adverse effect on transplantation outcome.
Blood. 2004;104:1923-1930.
